STS Medical Group
Meritxell Laguna is an experienced regulatory affairs professional currently serving as the Group Manager of Regulatory Affairs at STS Medical Group since October 2021, leading multi-site regulatory strategies and MDR projects. Prior roles include Regulatory Affairs Manager at Leventon, overseeing global regulatory affairs and vigilance reporting, and EMEA Product Surveillance Supervisor at Zimmer Biomet, where Meritxell managed complaint handling for medical devices and led a multicultural team. Additional experience encompasses regulatory roles at Alcoholes Montplet, INDIBA, Alcon Laboratories, Angelini, UQUIFA, CTC Pharma Logistics, and HARTMANN GROUP. Educational qualifications include an Executive Master in Business Administration and a Master of Business Administration from EAE Business School and Universitat Politècnica de Catalunya, respectively, along with a Master's degree in Pharmacovigilance and a Bachelor's degree in Pharmacy from Universitat de Barcelona. Meritxell also studied Hospital Pharmacy at Université Paris Cité as part of an Erasmus programme.
This person is not in any teams
This person is not in any offices
STS Medical Group
STS Medical Group is a fast-growing organization and a leading European player specialized in the manufacturing and distribution of custom procedure trays (CPT) and medical devices designed and customized for surgical theaters. The Group operates in four main lines of business: CPTs; CPT components such as drapes, gowns and gauze; protective clothing; and medical devices for surgical theatres in public and private hospitals, as well as for healthcare facilities, local health services, nursing homes, wholesalers, and pharmacies. Since its foundation STS Medical Group has believed there's one decision that is essential and non-negotiable: transparency. This is a key element to drive sustainability in healthcare. That's why STS is the first in the market to strongly highlight the transparency impact of adopting article 12 compared to article 11 of EU Medical Device Directive 93/42/EEC in the management of CPTs. To reinforce this transparency commitment, STS has developed the Secu family brand that highlight our pledge to never compromise on the quality and security of our products and services STS Medical Group operates through Sengewald, MSP Schmeiser, MSS Medical Set Service, Salvadori and STS Bulgarian Manufacturing Hub, and from Germany, Italy and Bulgaria reaches all the main European markets. Out of the five production plants, three are located in Germany and two in Sandanski, Bulgaria, where STS Medical Group now benefits from one of the largest and most technologically advanced production hubs for medical devices in Europe. Moreover, STS has just opened a new commercial office in Singapore to deliver its transparent and ready-to-use solutions to the fast-developing Asian healthcare market. STS Medical Group is owned by Monitor Clipper Partners, a private equity firm based in Boston (Massachusetts) and Zurich (Switzerland) and Luxembourg, and Augusto Orsini, an executive with over 25 years of experience in the surgical theater solutions market.